| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ACTINOGEN MEDICAL LIMITED: Change in substantial holding | 1 | ASX | ||
| 15.05. | Actinogen Medical - Funding in place through key catalysts | 123 | Edison Investment Research | Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering ('entitlement offer') designed to raise up to A$3.9m... ► Artikel lesen | |
| 15.05. | ACTINOGEN MEDICAL LIMITED: ACWs $3.9m entitlement offer opens & letters distribute | - | ASX | ||
| 14.05. | ACTINOGEN MEDICAL LIMITED: Notification regarding unquoted securities - ACW | 2 | ASX | ||
| 14.05. | ACTINOGEN MEDICAL LIMITED: Cleansing Notice | 1 | ASX | ||
| 14.05. | ACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW | 1 | ASX | ||
| 12.05. | ACTINOGEN MEDICAL LIMITED: ACW Clinical Trials Science Forum 23 May registration detail | 1 | ASX | ||
| 08.05. | ACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW | 2 | ASX | ||
| 07.05. | ACTINOGEN MEDICAL LIMITED: ACW lodges Prospectus for entitlement offer of up to $3.9m | - | ASX | ||
| 07.05. | ACTINOGEN MEDICAL LIMITED: Prospectus - Non-renounceable Entitlement Offer | - | ASX | ||
| 03.05. | Australia's Actinogen plunges on discounted capital raising | 1 | Reuters | ||
| 03.05. | ACTINOGEN MEDICAL LIMITED: Proposed issue of securities - ACW | - | ASX | ||
| 03.05. | ACTINOGEN MEDICAL LIMITED: Actinogen announces capital raising of up to $8.9 million | - | ASX | ||
| 01.05. | ACTINOGEN MEDICAL LIMITED: Trading Halt | 1 | ASX | ||
| 30.04. | ACTINOGEN MEDICAL LIMITED: ACW March 2024 quarterly activity report & Appendix 4C | 1 | ASX | ||
| 22.04. | ACTINOGEN MEDICAL LIMITED: ACW completes cognition & depression phase 2 trial enrolment | - | ASX | ||
| 16.04. | Actinogen Medical - First patient dosed in Phase IIb XanaMIA study | 134 | Edison Investment Research | Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol... ► Artikel lesen | |
| 15.04. | Actinogen Medical Limited: First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial | 232 | PR Newswire | Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease
Enrolment... ► Artikel lesen | |
| 15.04. | Actinogen Medical launches Alzheimer's trial to test impact of Xanamem on cognitive health | 1 | smallcaps.com.au | ||
| 15.04. | ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer's | 1 | Stockhead |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 4.030 |
| NVIDIA | 2.794 |
| GAMESTOP | 2.791 |
| NEL | 2.766 |
| TUI | 2.362 |
| BAYER | 1.568 |
| REDCARE PHARMACY | 1.353 |
| RHEINMETALL | 1.256 |
| PLUG POWER | 1.240 |
| SIEMENS ENERGY | 1.212 |
| TESLA | 1.094 |
| BYD | 1.070 |
| VOLKSWAGEN | 1.034 |
| MERCEDES-BENZ | 1.024 |
| DEUTSCHE LUFTHANSA | 1.020 |
| AIXTRON SE | 1.014 |
| COMMERZBANK | 1.013 |
| RENK GROUP | 909 |
| DEUTSCHE BANK | 887 |
| THYSSENKRUPP NUCERA | 794 |
| SUPER MICRO COMPUTER | 776 |
| BASF | 744 |
| THYSSENKRUPP | 724 |
| AMC ENTERTAINMENT | 699 |
| RWE | 678 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
